Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 32, Number 9—September 2026

CME ACTIVITY - Synopsis

Neoehrlichiosis Causing Hemolytic Anemia in Patients Treated with Rituximab, Norway, 2024–2025

Martin PaulsonComments to Author , Christine Wennerås, Hanne Quarsten, Kristine K. Berg, Anders L. Drivenes, Magnus Moksnes, and Tor Henrik A. Tvedt
Author affiliation: Vestfold Hospital Trust, Tønsberg, Norway (M. Paulson, M. Moksnes); University of Gothenburg, Gothenburg Sahlgrenska Academy, Gothenburg, Sweden (C. Wennerås); Sahlgrenska University Hospital, Gothenburg (C. Wennerås); Sørlandet Hospital Trust, Kristiansand, Norway (H. Quarsten, K.K. Berg); Oslo University Hospital, Oslo, Norway (A.L. Drivenes, T.H.A. Tvedt); University of Oslo Institute of Clinical Medicine, Oslo (T.H.A. Tvedt)

Main Article

Figure

Hemoglobin levels (blue line) for patient 1 in a case series of 3 patients with neoehrlichiosis and hemolytic anemia at admission, during disease course, and after treatment with antibiotics, Norway, 2024–2025.

Figure. Hemoglobin levels (blue line) for patient 1 in a case series of 3 patients with neoehrlichiosis and hemolytic anemia at admission, during disease course, and after treatment with antibiotics, Norway, 2024–2025.

Main Article

Page created: August 31, 2026
Page updated: August 31, 2026
Page reviewed: August 31, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external